Bio-Key Intl Inc Financials

BKYI

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Bio-Key Intl Inc (BKYI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BKYI FY2025 2026-06-22

BIO-key sells a high-gross-margin offering, but its overhead-heavy cost structure keeps the business cash-consuming at current scale.

From FY2023 to FY2025, gross margin recovered from 18.5% to 76.9%. Even so, operating cash burn stayed around -$4M a year and closely tracked reported losses, which implies the drag is less about product-level economics or capex and more about a fixed expense base that this revenue level still cannot absorb.

FY2025 shows the company can retain much of each sales dollar above delivery cost: gross profit was $4.6M on $5.9M of revenue. But SG&A plus R&D still exceeded sales, so the main bottleneck is operating scale rather than whether the product can be sold at a healthy gross spread. The sharp margin rebound after FY2023 also suggests mix volatility or fulfillment-cost swings, not a smooth scale story.

The liquidity picture improved in FY2025, with cash rising to $2.7M and the current ratio returning to 1.5x. But that repair came from external capital: financing inflow of $6.9M more than covered the operating shortfall. Because capex was only $12K, this is an asset-light burn, meaning cash is being spent mainly on ongoing operations rather than building physical capacity.

Financial Health Signals

Financial Profile 21/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Bio-Key Intl Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Bio-Key Intl Inc has an operating margin of -115.0%, meaning the company retains $-115 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -57.9% the prior year.

Growth

Bio-Key Intl Inc's revenue declined 14.3% year-over-year, from $6.9M to $5.9M. This contraction results in a growth score of 13/100.

Leverage

Bio-Key Intl Inc carries a low D/E ratio of 0.63, meaning only $0.63 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Bio-Key Intl Inc's current ratio of 1.47 is below the typical benchmark, resulting in a score of 25/100. However, the company holds substantial cash reserves (87% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Cash Flow

While Bio-Key Intl Inc generated -$4.7M in operating cash flow, capex of $12K consumed most of it, leaving -$4.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Bio-Key Intl Inc generates a -140.2% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -114.0% the prior year.

Piotroski F-Score Weak

3/9

Bio-Key Intl Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Low Quality

0.65x

For every $1 of reported earnings, Bio-Key Intl Inc generates $0.65 in operating cash flow (-$4.7M OCF vs -$7.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-112.3x

Bio-Key Intl Inc earns $-112.3 in operating income for every $1 of interest expense (-$6.8M vs $61K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$5.9M

YoY-14.3%

5Y CAGR+15.9%

10Y CAGR+1.2%

Bio-Key Intl Inc generated $5.9M in revenue in fiscal year 2025. This represents a decrease of 14.3% from the prior year.

EBITDA

-$6.7M

YoY-72.1%

Bio-Key Intl Inc's EBITDA was -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 72.1% from the prior year.

Net Income

-$7.2M

YoY-66.4%

Bio-Key Intl Inc reported -$7.2M in net income in fiscal year 2025. This represents a decrease of 66.4% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$4.7M

YoY-59.9%

Bio-Key Intl Inc generated -$4.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 59.9% from the prior year.

Cash & Debt

$2.7M

YoY+515.8%

5Y CAGR-30.8%

10Y CAGR-4.6%

Bio-Key Intl Inc held $2.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+192.0%

Bio-Key Intl Inc had 1M shares outstanding in fiscal year 2025. This represents an increase of 192.0% from the prior year.

Margins & Returns

Gross Margin

76.9%

YoY-4.5pp

5Y CAGR+4.9pp

10Y CAGR+1.2pp

Bio-Key Intl Inc's gross margin was 76.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 4.5 percentage points from the prior year.

Operating Margin

-115.0%

YoY-57.1pp

5Y CAGR+68.4pp

10Y CAGR-82.7pp

Bio-Key Intl Inc's operating margin was -115.0% in fiscal year 2025, reflecting core business profitability. This is down 57.1 percentage points from the prior year.

Net Margin

-120.5%

YoY-58.5pp

5Y CAGR+220.5pp

10Y CAGR-85.3pp

Bio-Key Intl Inc's net profit margin was -120.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 58.5 percentage points from the prior year.

Return on Equity

-140.2%

YoY-26.1pp

5Y CAGR-92.6pp

10Y CAGR-129.9pp

Bio-Key Intl Inc's ROE was -140.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 26.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$2.6M

YoY+3.9%

5Y CAGR+13.3%

10Y CAGR+5.3%

Bio-Key Intl Inc invested $2.6M in research and development in fiscal year 2025. This represents an increase of 3.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$12K

YoY-7.9%

5Y CAGR-19.5%

10Y CAGR+13.6%

Bio-Key Intl Inc invested $12K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 7.9% from the prior year.

BKYI Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$5.9M-14.3%	$6.9M-10.6%	$7.8M+10.5%	$7.0M+37.3%	$5.1M+80.3%	$2.8M
Cost of Revenue	$1.4M+6.5%	$1.3M-79.6%	$6.3M+159.2%	$2.4M+45.8%	$1.7M+110.5%	$795K
Gross Profit	$4.6M-19.1%	$5.6M+294.1%	$1.4M-68.8%	$4.6M+33.1%	$3.4M+68.5%	$2.0M
R&D Expenses	$2.6M+3.9%	$2.5M+4.9%	$2.4M-26.4%	$3.3M+38.1%	$2.4M+68.6%	$1.4M
SG&A Expenses	$6.3M-12.0%	$7.1M-9.2%	$7.9M-16.0%	$9.4M+55.3%	$6.0M+3.1%	$5.8M
Operating Income	-$6.8M-70.2%	-$4.0M+54.6%	-$8.8M+11.1%	-$9.9M-100.8%	-$4.9M+5.0%	-$5.2M
Interest Expense	$61K-65.4%	$176K-19.5%	$218K+1986.3%	$10K-41.9%	$18K-99.6%	$4.3M
Income Tax	$17K+171.7%	-$23K+82.8%	-$134K-555.8%	-$20K	$0	$0
Net Income	-$7.2M-66.4%	-$4.3M+49.5%	-$8.5M+28.4%	-$11.9M-135.1%	-$5.1M+47.6%	-$9.7M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$2.1M+98.0%	$1.1M-30.1%	$1.5M-8.7%	$1.7M+5.6%	$1.6M+9.9%	$1.5M-31.8%	$2.1M+87.9%	$1.1M
Cost of Revenue	$376K+38.7%	$271K-24.2%	$358K-22.9%	$464K+66.1%	$279K+6.5%	$262K-43.6%	$465K+77.3%	$262K
Gross Profit	$1.8M+117.8%	$812K-31.8%	$1.2M-3.3%	$1.2M-7.2%	$1.3M+10.6%	$1.2M-28.6%	$1.7M+91.1%	$879K
R&D Expenses	$617K-11.2%	$694K+1.6%	$684K+7.5%	$636K+6.8%	$596K-9.8%	$660K+1.2%	$652K+10.3%	$591K
SG&A Expenses	$1.3M-28.4%	$1.8M+30.6%	$1.4M-16.7%	$1.7M+22.4%	$1.4M-24.1%	$1.8M+12.4%	$1.6M-17.2%	$1.9M
Operating Income	-$158K+96.3%	-$4.2M-372.0%	-$892K+17.7%	-$1.1M-69.2%	-$641K+49.5%	-$1.3M-118.4%	-$580K+64.9%	-$1.7M
Interest Expense	$27K+295.0%	-$14K-205.7%	$13K-48.6%	$26K-28.6%	$36K-46.3%	$67K-32.1%	$99K+1006.1%	$9K
Income Tax	$0-100.0%	$17K	$0	$0	$0+100.0%	-$23K	$0	$0
Net Income	-$205K+95.2%	-$4.3M-344.5%	-$965K+17.4%	-$1.2M-58.5%	-$737K+46.8%	-$1.4M-87.4%	-$739K+55.7%	-$1.7M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BKYI Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.3M-3.6%	$8.6M+90.7%	$4.5M-60.2%	$11.3M-36.2%	$17.8M-21.1%	$22.5M
Current Assets	$4.5M+140.5%	$1.9M-28.0%	$2.6M-70.8%	$9.0M-35.9%	$14.0M-26.0%	$18.9M
Cash & Equivalents	$2.7M+515.8%	$438K-14.4%	$511K-80.6%	$2.6M-66.0%	$7.8M-54.4%	$17.0M
Inventory	$371K-2.0%	$378K-15.1%	$446K-89.9%	$4.4M-10.2%	$4.9M+1392.9%	$331K
Accounts Receivable	$1.2M+70.0%	$718K-40.2%	$1.2M-21.1%	$1.5M+56.9%	$971K+77.1%	$548K
Goodwill	N/A	N/A	N/A	$0-100.0%	$1.3M0.0%	$1.3M
Total Liabilities	$3.2M-34.0%	$4.8M+40.3%	$3.5M-42.8%	$6.0M+180.6%	$2.2M-1.5%	$2.2M
Current Liabilities	$3.1M-32.0%	$4.6M+41.7%	$3.2M-41.1%	$5.5M+172.9%	$2.0M+6.6%	$1.9M
Long-Term Debt	N/A	$45K-76.3%	$189K-42.2%	$327K	$0	N/A
Total Equity	$5.1M+35.4%	$3.8M+254.7%	$1.1M-79.9%	$5.3M-66.0%	$15.6M-23.2%	$20.3M
Retained Earnings	-$136.5M-5.5%	-$129.3M-3.4%	-$125.0M-7.3%	-$116.5M-11.4%	-$104.6M-5.1%	-$99.5M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$8.2M-1.8%	$8.3M-17.9%	$10.1M-3.8%	$10.5M-6.0%	$11.2M+29.8%	$8.6M+34.6%	$6.4M+33.4%	$4.8M
Current Assets	$4.5M-1.1%	$4.5M+21.1%	$3.7M-7.2%	$4.0M-12.1%	$4.6M+143.2%	$1.9M-58.5%	$4.6M+50.9%	$3.0M
Cash & Equivalents	$2.2M-16.6%	$2.7M+32.1%	$2.0M-10.3%	$2.3M-27.4%	$3.1M+616.1%	$438K-75.7%	$1.8M+42.9%	$1.3M
Inventory	$338K-8.8%	$371K-5.9%	$394K+23.7%	$319K-11.0%	$358K-5.4%	$378K-2.2%	$387K-10.7%	$433K
Accounts Receivable	$1.6M+28.9%	$1.2M+27.2%	$960K-2.4%	$984K+22.4%	$803K+11.8%	$718K-62.8%	$1.9M+113.5%	$904K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.3M+2.1%	$3.2M-21.4%	$4.1M+11.0%	$3.7M+0.2%	$3.7M-24.5%	$4.8M-22.7%	$6.3M+7.0%	$5.9M
Current Liabilities	$3.2M+3.0%	$3.1M+4.5%	$3.0M-16.1%	$3.5M+1.9%	$3.5M-23.9%	$4.6M-22.4%	$5.9M+5.3%	$5.6M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$12K-73.9%	$45K-46.6%	$84K-26.8%	$115K
Total Equity	$4.9M-4.2%	$5.1M-15.5%	$6.0M-11.8%	$6.9M-9.0%	$7.5M+99.5%	$3.8M+2735.2%	$133K+112.6%	-$1.1M
Retained Earnings	-$136.7M-0.2%	-$136.5M-3.2%	-$132.2M-0.7%	-$131.2M-0.9%	-$130.0M-0.6%	-$129.3M-1.1%	-$127.9M-0.6%	-$127.2M

BKYI Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$4.7M-60.2%	-$2.9M+23.2%	-$3.8M+39.1%	-$6.2M+30.6%	-$9.0M-81.4%	-$5.0M
Capital Expenditures	$12K-7.9%	$13K+1204.7%	$1K-98.8%	$82K+95.2%	$42K+18.2%	$36K
Free Cash Flow	-$4.7M-59.9%	-$2.9M+22.9%	-$3.8M+39.9%	-$6.3M+30.0%	-$9.0M-80.9%	-$5.0M
Investing Cash Flow	-$12K+7.9%	-$13K-1204.7%	-$1K+99.9%	-$697K-1557.7%	-$42K+98.1%	-$2.2M
Financing Cash Flow	$6.9M+144.5%	$2.8M+97.2%	$1.4M-24.7%	$1.9M+970.7%	-$219K-100.9%	$24.1M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$358K+80.4%	-$1.8M-63.0%	-$1.1M-27.6%	-$880K-5.4%	-$835K-62.3%	-$515K+59.7%	-$1.3M+10.2%	-$1.4M
Capital Expenditures	$0-100.0%	$5K+250.1%	$1K-10.4%	$1K-67.7%	$5K+145.7%	-$10K-147.2%	$21K	$0
Free Cash Flow	-$358K+80.5%	-$1.8M-63.3%	-$1.1M-27.5%	-$881K-5.0%	-$840K-60.1%	-$525K+59.6%	-$1.3M+8.7%	-$1.4M
Investing Cash Flow	$0+100.0%	-$5K-250.1%	-$1K+10.4%	-$1K+67.7%	-$5K-145.7%	$10K+147.2%	-$21K	$0
Financing Cash Flow	-$38K-101.6%	$2.5M+155.2%	$963K+2794.4%	-$36K-101.0%	$3.5M+523.4%	-$834K-147.7%	$1.7M-11.1%	$2.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BKYI Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	76.9%-4.5pp	81.4%+62.9pp	18.5%-46.8pp	65.3%-2.0pp	67.3%-4.7pp	72.0%
Operating Margin	-115.0%-57.1pp	-57.9%+55.9pp	-113.8%+27.5pp	-141.4%-44.7pp	-96.6%+86.8pp	-183.4%
Net Margin	-120.5%-58.5pp	-62.1%+47.8pp	-109.9%+59.8pp	-169.6%-70.6pp	-99.1%+242.0pp	-341.0%
Return on Equity	-140.2%-26.1pp	-114.0%+687.2pp	-801.2%-576.6pp	-224.7%-192.2pp	-32.4%+15.1pp	-47.6%
Return on Assets	-86.2%-36.3pp	-49.9%+138.7pp	-188.7%-83.7pp	-105.0%-76.5pp	-28.5%+14.4pp	-43.0%
Current Ratio	1.47+1.1	0.41-0.4	0.82-0.8	1.65-5.4	7.01-3.1	10.10
Debt-to-Equity	0.63+0.6	0.01-0.2	0.18+0.1	0.06+0.1	0.00-0.1	0.11
FCF Margin	-78.8%-36.6pp	-42.2%+6.7pp	-48.9%+41.0pp	-89.9%+86.5pp	-176.4%-0.6pp	-175.8%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	82.5%+7.5pp	75.0%-1.9pp	76.9%+4.2pp	72.7%-10.0pp	82.6%+0.5pp	82.1%+3.7pp	78.3%+1.3pp	77.0%
Operating Margin	-7.3%+381.2pp	-388.5%-331.0pp	-57.6%+6.3pp	-63.9%-24.0pp	-39.9%+46.8pp	-86.7%-59.6pp	-27.1%+117.9pp	-144.9%
Net Margin	-9.6%+386.2pp	-395.8%-333.5pp	-62.3%+6.5pp	-68.8%-23.0pp	-45.8%+48.9pp	-94.7%-60.2pp	-34.4%+111.6pp	-146.1%
Return on Equity	-4.2%+79.8pp	-84.0%-68.0pp	-16.0%+1.1pp	-17.0%-7.2pp	-9.8%+26.9pp	-36.7%+518.7pp	-555.4%	N/A
Return on Assets	-2.5%+49.1pp	-51.7%-42.1pp	-9.5%+1.6pp	-11.1%-4.5pp	-6.6%+9.5pp	-16.1%-4.5pp	-11.6%+23.2pp	-34.7%
Current Ratio	1.41-0.1	1.47+0.2	1.26+0.1	1.14-0.2	1.32+0.9	0.41-0.4	0.78+0.2	0.54
Debt-to-Equity	0.67+0.0	0.63-0.0	0.67+0.7	0.000.0	0.00-0.0	0.01-0.6	0.63+0.7	-0.11
FCF Margin	-16.7%+152.7pp	-169.3%-96.8pp	-72.5%-20.6pp	-51.9%+0.3pp	-52.3%-16.4pp	-35.9%+24.6pp	-60.5%+64.0pp	-124.5%

Similar Companies

Iveda Solutions IVDA

$4.0M

SU Group Holdings Limited SUGP

$3.7M

Verifyme Inc VRME

$8.2M

Guardforce AI GFAI

$12.2M

Supercom SPCB

$62.7M

Frequently Asked Questions

What is Bio-Key Intl Inc's annual revenue?

Bio-Key Intl Inc (BKYI) reported $5.9M in total revenue for fiscal year 2025. This represents a -14.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Bio-Key Intl Inc's revenue growing?

Bio-Key Intl Inc (BKYI) revenue declined by 14.3% year-over-year, from $6.9M to $5.9M in fiscal year 2025.

Is Bio-Key Intl Inc profitable?

No, Bio-Key Intl Inc (BKYI) reported a net income of -$7.2M in fiscal year 2025, with a net profit margin of -120.5%.

What is Bio-Key Intl Inc's EBITDA?

Bio-Key Intl Inc (BKYI) had EBITDA of -$6.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Bio-Key Intl Inc's gross margin?

Bio-Key Intl Inc (BKYI) had a gross margin of 76.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Bio-Key Intl Inc's operating margin?

Bio-Key Intl Inc (BKYI) had an operating margin of -115.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Bio-Key Intl Inc's net profit margin?

Bio-Key Intl Inc (BKYI) had a net profit margin of -120.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Bio-Key Intl Inc's return on equity (ROE)?

Bio-Key Intl Inc (BKYI) has a return on equity of -140.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Bio-Key Intl Inc's free cash flow?

Bio-Key Intl Inc (BKYI) generated -$4.7M in free cash flow during fiscal year 2025. This represents a -59.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Bio-Key Intl Inc's operating cash flow?

Bio-Key Intl Inc (BKYI) generated -$4.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Bio-Key Intl Inc's total assets?

Bio-Key Intl Inc (BKYI) had $8.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Bio-Key Intl Inc's capital expenditures?

Bio-Key Intl Inc (BKYI) invested $12K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Bio-Key Intl Inc spend on research and development?

Bio-Key Intl Inc (BKYI) invested $2.6M in research and development during fiscal year 2025.

How many shares does Bio-Key Intl Inc have outstanding?

Bio-Key Intl Inc (BKYI) had 1M shares outstanding as of fiscal year 2025.

What is Bio-Key Intl Inc's current ratio?

Bio-Key Intl Inc (BKYI) had a current ratio of 1.47 as of fiscal year 2025, which is considered adequate.

What is Bio-Key Intl Inc's debt-to-equity ratio?

Bio-Key Intl Inc (BKYI) had a debt-to-equity ratio of 0.63 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Bio-Key Intl Inc's return on assets (ROA)?

Bio-Key Intl Inc (BKYI) had a return on assets of -86.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Bio-Key Intl Inc's cash runway?

Based on fiscal year 2025 data, Bio-Key Intl Inc (BKYI) had $2.7M in cash against an annual operating cash burn of $4.7M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Bio-Key Intl Inc's Piotroski F-Score?

Bio-Key Intl Inc (BKYI) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Bio-Key Intl Inc's earnings high quality?

Bio-Key Intl Inc (BKYI) has an earnings quality ratio of 0.65x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Bio-Key Intl Inc cover its interest payments?

Bio-Key Intl Inc (BKYI) has an interest coverage ratio of -112.3x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Bio-Key Intl Inc?

Bio-Key Intl Inc (BKYI) scores 21 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.